Hiki et al.18 reported on 305 patients who underwent pylorus preserving gastrectomy and none of them had tumor recurrence. Kinami et al.19 reported the relationship between the frequency of the lymphatic basin within the right gastric artery and the distance from the pylorus to the distal margin of the tumor. Some patients with the distance less than 8 cm had lymphatic basin within the lymphatic compartment of the right gastric artery area. Thus, the pylorus preserving gastrectomy is the good operation for enrolling to the study of sentinel nodes. In conclusion, the present study shows that HEMS-guided abdominal surgery is feasible under room light. Submucosal injection of 0.5 mL × 4

of 50 µg/mL ICG on the day before operation is the adequate administration for detecting sentinel nodes using HEMS in the gastric cancer surgery. No potential Doxorubicin chemical structure conflict of interest has been declared by the authors. “
“Approximately 75% to 80% of hepatocellular carcinomas (HCC) worldwide are attributed to chronic hepatitis B virus (HBV) and chronic hepatitis C virus (HCV) infection. Thus, effective prevention of HBV and HCV infection selleck inhibitor and progression from acute HBV and HCV infection to chronic hepatitis, cirrhosis and HCC might prevent as many as 450 000 deaths from HCC each year. The most effective approach to preventing HCC is to prevent HBV and HCV infection through

vaccination. Indeed HBV vaccine is the first vaccine demonstrated to prevent cancers. However, a vaccine for HCV is not available and for persons who are chronically infected with HBV or HCV, antiviral therapy is the only option for preventing HCC.

Direct evidence supporting a benefit of antiviral therapy on the prevention of HCC has been shown in a few randomized controlled trials. There is abundant evidence that antiviral therapy, in patients with long-term virological response, can improve liver histology, providing indirect support that antiviral therapy may prevent HCC by slowing progression N-acetylglucosamine-1-phosphate transferase of liver disease and possibly even reversing liver damage. Nevertheless, the risk of HCC remains in patients with chronic HBV or chronic HCV infection if treatment is initiated after cirrhosis is established. These data indicate that treatment might be of greater benefit if instituted earlier in the course of chronic hepatitis B or C. Safer, more effective, and more affordable antiviral therapies are needed for both hepatitis B and hepatitis C so more patients can benefit from treatment and more HCCs can be prevented. “
“Resistance rates of H. pylori to clarithromycin, metronidazole and quinolone are over 30% in S. Korea. Aim of this prospective study was to evaluate the ultimate eradication rate of H. pylori after 1st, 2nd or 3rd line therapy in Korea. A cohort of 2,202 patients with H. pylori was treated with proton pump inhibitor (PPI)-based triple therapy for 7 days.